Skip to Content
Søg Menu

Update om behandling af myelomatose med bispecifikke antitoffer

Hør i denne MEDtalk om Agoston Gyula Szabos perspektivering af tre studier, præsenteret ved ASH 2021, omhandlende behandling af myelomatose med bispecifikt antistof.

Agoston Gyula Szabos

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Fredrik Hellem Schjesvold

Melflufen is Safe and Effective in Patients with Alkylator-Refractory Disease

/ Fredrik Schjesvold
Myelomatose Play the Video 4:41
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelomatose Play the Video 05:04
Agoston Gyula Szabo

Myelomatose: Interessante data fra investigator-initieret studier

/ Agoston Gyula Szabo
ASH23Myelomatose Play the Video 7:42
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video 6:39

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose
Fredrik Schjesvold

EHA23 Insights into the Changing Landscape of Myeloma Treatments

/ Fredrik Schjesvold
EHA23Myelomatose Play the Video 4:39
Sagar Lonial

Exciting News for CAR T Cell Therapy to Heavily Treated Patients with Multiple Myeloma

/ Sagar Lonial
ASCO23CAR-TEHA23Myelomatose Play the Video 02:20
Rakesh Popat

Integrating BCMA-Based Combination Regimens in Early R/R Multiple Myeloma

/ Rakesh Popat
EHA23Myelomatose Play the Video 03:23

High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma

/ Katrine Fladeland Iversen
MyelomatoseT-celler
Back to top